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Introduction
Bronchial asthma has emerged as the most 
common non-communicable respiratory disease 
affecting children worldwide [1], and its prevalence is 
increasing. The causes and pathogenesis of bronchial 
asthma are not completely understood [1], [2], and it 
is becoming increasingly apparent that the disease 
is heterogeneous with respect to immune-pathology, 
clinical phenotypes, response to therapies, and natural 
history [3]. Precision in diagnosis and treatment has 
become imperative for the achievement of better 
outcomes [4]. In practice, a panel of biomarkers is 
needed to indicate the various underlying disease 
pathologies and enable the definitive categorization of 
asthmatics into distinct sub-phenotypes [5].
A potential for iron-catalyzed oxidative stress 
in asthma was reported [6], and proteomic discovery 
program has identified a panel of proteins indicating the 
involvement of iron metabolism pathway in asthma [7]. 
Ceruloplasmin (Cp), haptoglobin, and hemopexin are 
predominantly liver-synthesized acute phase proteins 
that play a role in iron homeostasis and have important 
anti-inflammatory activity through inhibition of oxidative 
stress and iron sequestration resulting in antimicrobial 
activity [7], [8].
Cp regulates body iron homeostasis by its 
capacity to oxidize the highly toxic ferrous form of iron 
to the relatively nontoxic ferric form. Cp is required for 
efficient iron release from cells and tissues [9]. The 
inhibition of heme releases from globin by haptoglobin 
and sequestration of heme by hemopexin, suppress 
hemoglobin-mediated oxidative stress, attenuates 
endothelial cytotoxicity, and protects cells from heme 
toxicity [10].
These proteins may function to modulate 
the systemic inflammatory response to inflammation 
and be involved in tissue repair through fibrosis and 
angiogenesis [7]. We hypothesized that these proteins 
could be biological markers for bronchial asthma that 
reflect the involvement of iron in asthma pathogenesis 
and protect against iron oxidative stress.
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We aimed to evaluate the serum levels of 
proteins involved in iron homeostasis (Cp, hemopexin, 
and haptoglobin) in asthmatic children and their 
correlation to pulmonary functions.
Materials and Methods
The study was case–control one, included 60 
chronic asthmatic children aged 6–13 years 30 recruited 
during attacks (Group I) and 30 recruited in-between 
attacks (Group II), they were recruited from Pulmonology 
and Allergy Clinic, Children’s Hospital, Cairo University. 
Inclusion criteria: Patients suffering from asthma solely, 
based on careful history and physical examination as 
well as a documented reversible and variable airflow 
obstruction as described in GINA were included in the 
study [11].
Exclusion criteria
Patients with mild persistent or intermittent 
asthma, patients receiving inhaled corticosteroids or 
leukotriene antagonists within 1 week or receiving oral 
corticosteroids within 3 weeks before inclusion in the 
study, patients suffering from other chronic illnesses 
(diabetes mellitus, kidney disease, liver disease, 
or thyroid dysfunction), conditions that can alter 
acute phase reactants including patients with acute 
(within 1 week) and chronic inflammatory disorders, 
patients with neuromuscular disorders, patients with 
hemolytic anemia, Wilson’s disease, lymphoma, and 
rheumatoid arthritis. Thirty non-atopic, non-asthmatic 
age- and sex-matched healthy control children 
(Group III) were also included. They were recruited 
from Ophthalmology Clinic, Children’s Hospital, 
Cairo University. The study has been approved by 
the Ethical Committee of the National Research 
Centre. All patients’ guardians gave informed written 
consent.
All candidates were subjected to detailed 
history taking, clinical evaluation, and assessments of 
pulmonary function tests (for patients). Venous blood 
samples were collected from all included children for the 
assessment of complete blood count, total serum IgE 
level (using ELIZA DRG International Inc Kit (USA), and 
assessment of serum Cp, hemopexin, and haptoglobin 
(using ELIZA assay pro Kits (Missouri, USA).
Statistical analysis
Data were analyzed using the GraphPad 
prism version 6. t-test was used to compare between 
two groups, and ANOVA test was used for comparison 
between more than two groups. For quantitative 
variables, mean, standard deviation was presented. 
Correlation to estimate the association between 
quantitative variables was presented in the form of 
correlation coefficient (r) and its significance. p < 0.05 
was considered statistically significant.
Results
The study included 19 males (53.3%) and 
11 females (36.7%) in Group I, 16 male (63.3%) and 
14 females (46.7%) in Group II, no significant difference 
was detected (p = 0.601) between both. Positive family 
history was present in 24 (80%) of Group I and 15 (50%) 
of Group II. Comparison between asthmatics (Groups I 
and II) and controls regarding demographic, clinical, 
and lab data are presented in Table 1.
The mean serum level of Cp exhibited 
significantly higher values in Group II compared to 
Group I (p = 0.014) and in both Groups I and II, compared 
to controls (p = 0.004 and p = 0.0002 respectively), 
Table 1 and Figure 1.
The mean serum level of haptoglobin exhibited 
higher values in Group II compared to Group I (p = 0.006) 
and control subjects (p < 0.0001). The difference 
between Group I and control was insignificant (p = 0.1) 
(Table 1 and Figure 2).
The mean serum level of hemopexin exhibited 
higher values in Group I and Group II compared to 
control subjects (p = 0.02, 0.003, respectively) but the 
difference between both Groups I and II was insignificant 
(p = 0.7), (Table 1 and Figure 2).
No significant correlations were found between 
any of the previous protein levels assessed and 
pulmonary functions or any other variable in the study, 
as presented in Table 2.
Discussion
Identifying biomarkers involved in asthma 
pathogenesis could have a possible role in bridging 
the diagnostic gap [4] and the creation of personalized 
treatment regimens [5]. The current study demonstrated 
differential expressions of Cp, haptoglobin, and 
hemopexin among our clinical groups.
Cp is a sensitive acute phase reactant, which 
increases during acute and chronic inflammatory 
processes [12]. There is experimental evidence that 
some cell types in the lungs and airways may have 
the potential to produce Cp [13]. It has significant 
antioxidant capacity and can reduce lipid peroxidation 
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induced by metal ions and peroxyl radicals, which 
in turn decreases cellular damage induced by toxic 
peroxidation products [14].
In our study, there was a significant higher 
Cp serum level in stable asthma and acute asthma 
exacerbation groups compared to controls. This agreed 
with Verrills et al. [7], Ermis et al. [15], and Vural and 
Uzun [16] who found significant higher Cp serum 
level in stable asthmatics compared to controls. Cp 
was significantly lower in acute asthma exacerbation 
when compared to stable asthma. This may be due to 
consumption during acute attacks for protection of the 
lungs, as reported by Farkhutdinov and Farkhutdinov [17] 
who indicated that Cp use in the combination therapy of 
asthma exacerbation resulted in a reduction in reactive 
oxygen species generation and contributed to positive 
changes in the clinical symptoms of asthma. Another 
explanation is a possibility of leakage of this protein 
from the blood to tissue during acute exacerbations; 
this assumption was supported by Van Rensen 
et al. [18] who reported increased concentrations of Cp 
in the sputum of asthmatics 30 min following inhalation 
challenge with substance P as compared to before the 
challenge; moreover, the sputum-to-serum ratios for Cp 
increased significantly after the challenge.
Haptoglobin is increased in alveolar 
macrophages and eosinophils in diseased or inflamed 
Table 1: Demographic, clinical, and lab data of the studied groups
Variable Group (I) asthmatics during 
acute attacks (n=30)
Group II asthmatics 
between the attacks (n=30)
Group III 
controls (n=30)
p-value
Mean±SD Mean±SD Mean±SD
Age (years) 9.5±2.366 8.4±2.14 8.96±2.01 0.08 between Groups I and II 0.97 between Group III 
and all asthmatics age (8.977±2.34)
Age of onset of asthma (months) 26.9±20.2 22.6±18.3 0.4
Height (cm) 134.3±15.64 128.5±14.81 132.1±12.2 0.14
Weight (kg) 32.77±12.36 29.07±10.6 31.65±10.5 0.21
Body mass index 17.45±3.06 16.8±2.4 17.8±2.8 0.4
Hemoglobin (g/dl) 12.47±1.01 13.4±1.3 12.2±1 Group I versus II=0.002*
Group I versus control=0.4
Group II versus control=0.0003*
Platelets Χ 103/ul 297.7±91.7 289.2±81.5 259.8 ± 70.05 Group I versus II=0.7
Group I versus control=0.07
Group II versus control=0.1
Leukocytic count Χ 103/uL 11.5±4.14 9.5±3.2 6.2±2.5 Group I versus II=0.03*
Group I versus control <0.0001*
Group II versus control <0.0001*
Absolute eosinophil count/cu mm 833.67±351.09 569.6±336.92 135±34.63 Group I versus II=0.004*
Group I versus control <0.0001*
Group II versus control <0.0001*
IgE (IU/ml) 235.52±159.2 125.64±149.9 55.11±20.75 Group I versus II=0.007*
Group I versus control <0.0001*
Group II versus control=0.01*
Ceruloplasmin (mg/dl) 288.8±219.6 448.04±386.79 168.42±13.46 Group I versus II=0.014*
Group I versus. control =0.004*
Group II versus control=0.0002*
Haptoglobin (µg/ml) 620±467.86 993.33±554.56 473.33±350.3 Group I versus II=0.006*
Group I versus control=0.1
Group II versus control <0.0001*
Hemopexin (µg/ml) 477.33±396.6 509.33±341.51 296.67±158.38 Group I versus II =0.7
Group I versus control =0.02*
Group II versus control =0.003*
*p<0.05 is significant.
Figure 1: Comparison between mean serum levels of ceruloplasmin 
in Group I, Group II, and control children
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Figure 2: Comparison between Group I, Group II, and control subjects 
regarding mean serum levels of haptoglobin and hemopexin
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tissues providing antioxidant and antimicrobial 
activity [19]. In our study, stable asthmatics exhibited 
significantly higher serum levels of haptoglobin 
compared to control subjects. This was consistent 
with the results demonstrated by Verrills et al. [7] and 
Kauffmann et al. [20]. The serum level of haptoglobin 
exhibited significant higher values in stable asthmatics 
compared to acute exacerbation. This agreed with 
Nishioka et al. [21]. Haptoglobin may be infused into the 
airways during the inflammatory process, which was 
supported by Larsen et al. [22]. Lamoureux et al. [23] 
have found that serum haptoglobin concentrations 
were significantly elevated in equine models of asthma 
during disease remission and after antigenic exposure 
compared to the control group. Variable serum 
levels of haptoglobin have been reported in asthma, 
either elevated [24], [25] or reduced [26]. Elevated 
haptoglobin in stable asthmatics (Group II) could be due 
to its involvement in tissue repair function [22] or to the 
kinetics of hepatic cellular response to cytokines [24]. 
The salivary concentrations of haptoglobin were 
found to be significantly higher in allergic asthmatic 
children [27].
A minor part of erythrocytes undergoes 
intravascular destruction, releasing hemoglobin 
which is bound by haptoglobin and the complexes is 
subsequently delivered to reticuloendothelial system, 
where they are internalized through receptor-mediated 
endocytosis. Haptoglobin, by binding hemoglobin and 
removing it from the circulation, prevents the iron-
stimulated formation of oxygen radicals and has an 
important role as an antioxidant [28]. Consistent with 
its role in modulating immune responses, haptoglobin 
at high levels was found to be related to AHR in 
asthma [25]. As part of its tissue repair function, 
haptoglobin can induce differentiation of fibroblast 
progenitor cells into lung fibroblasts and angiogenesis, 
potentially implicating haptoglobin in remodeling and 
fibrosis in asthma [22].
Hemopexin: In the current study, stable 
asthmatics exhibited higher mean serum levels of 
hemopexin compared to controls. This was consistent 
with the result of Verrills et al. [7]. Furthermore, we 
found higher serum levels of hemopexin during acute 
exacerbations compared to controls, which agreed with 
Haenen et al. [29] in murine models induced asthma. The 
serum level of hemopexin during acute exacerbations 
showed tendency to be lower than stable asthmatics, yet 
the change was statistically insignificant. This reduction 
may be justified by the expression of hemopexin in 
the airways, the same as haptoglobin do. Monferran 
et al. [30] have shown that the hemopexin domain of 
matrix metalloproteinase-9 (MMP-9) is important for 
the interactions of the metalloproteinase with the Ku 
heterodimer (Ku70/Ku80), a protein that plays a central 
role in DNA breaks repair. Interactions of Ku and MMP-9 
have been reported to be involved in remodeling of the 
extracellular matrix, which is a major cause of airway 
remodeling in asthma and is closely related to airway wall 
fibrosis and airflow limitation [31]. Studies found that the 
plasma level of total MMP-9 was significantly increased in 
patients with asthma in acute exacerbation and decreased 
in remission but remained elevated compared to healthy 
controls [32], [33]. These data suggest that hemopexin 
may be consumed during asthma exacerbation being an 
important factor for the activity of MMP-9.
The reduction in serum haptoglobin level during 
exacerbation compared to stable asthma was more 
noticeable than the reduction in hemopexin; this may 
be explained by the fact that only once haptoglobin is 
depleted, do levels of hemopexin begin to fall as reported 
by Muller-Eberhard et al. [34]. When the buffering capacity 
of haptoglobin is exceeded, hemoglobin liberates heme, 
which binds to albumin and is subsequently transferred 
to hemopexin [35]. Hemopexin binds heme with high 
affinity and delivers it to the liver to provide protection 
against free heme-mediated oxidative stress and to limit 
access by pathogens to heme. This contributes to iron 
homeostasis by recycling heme iron [36]. Free heme is 
highly toxic as it is a source of redox-active iron. In the 
cytoplasm, iron can participate in the Fenton reaction 
to produce the highly toxic reactive oxygen species 
that damage lipid membranes, proteins, and nucleic 
acids [37]. Significantly increased levels of hemopexin 
and haptoglobin, in broncho-alveolar lavage fluid of 
asthmatic patients compared to control subjects was 
reported [38].
No correlations were detected in the present 
study between the levels of Cp, haptoglobin, and 
hemopexin serum markers in all asthmatic patients 
and age. This agreed with Verrills et al. [7]. Serum Cp, 
haptoglobin, and hemopexin were not correlated to 
each other or to other different variables in the study 
(sex, age of onset of asthma, total serum IgE, and 
total eosinophilic count). Similarly, no correlation was 
found between Cp, haptoglobin, hemopexin, and lung 
functions. Vural and Uzun [16] demonstrated similar 
results concerning Cp.
Higher serum total leukocytic count was 
demonstrated during acute exacerbations and stable 
asthmatics compared to control subjects. These 
Table 2: Correlations between ceruloplasmin, haptoglobin, 
hemopexin, and different variables in asthmatic children
Variable Ceruloplasmin in 
all asthmatics
Haptoglobin in 
all asthmatics
Hemopexin in 
all asthmatics
n=60 n=60 n=60
r p r p r p
Age (years) −0.12 0.35 −0.1 0.4 −0.06 0.5
Age of onset of asthma (months) −0.07 0.5 −0.11 0.3 0.21 0.1
IgE (IU/ml) −0.01 0.9 0.06 0.6 −0.02 0.8
Absolute eosinophilia count 
(cells/cu mm)
−0.0004 0.99 −0.07 0.5 0.02 0.8
Forced expiratory volume 1 % 
pred.
0.13 0.32 −0.2 0.1 −0.02 0.82
Forced vital capacity % pred. 0.15 0.25 −0.24 0.06 0.019 0.88
Forced expiratory flow 25−75% 
pred.
−0.02 0.82 −0.08 0.5 −0.08 0.52
Peak expiratory flow % pred. −0.014 0.91 −0.03 0.8 −0.008 0.9
Haptoglobin (µg/ml) 0.1 0.17
Hemopexin (µg/ml) −0.1 0.43
Correlation between haptoglobin 
and hemopexin
0.009 0.9
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observations were agreed with Galez et al. [39]. Razi 
et al. [40] had similar data regarding acute exacerbation. 
Significantly elevated total leukocytic count during 
asthma exacerbation compared to stable asthma was 
found; this agreed by Belda et al. [41]. This confirmed 
an association between systemic inflammation and 
airway inflammation, as previously shown in different 
studies [42], [43]. Leukocytosis may also happen due to 
long-term use of β-agonist or steroid use [44].
Hemoglobin concentration was significantly 
higher among stable asthmatics compared to acute 
exacerbation group but no significant difference between 
acute exacerbation and control groups. These results 
are consistent with the findings of a study done by Weiss 
and Desforges [45]. Hemoglobin was significantly higher 
among stable asthmatics group compared to control 
which agreed with Guo et al. [46], Hailemaryam et al. [47], 
and Ejaz et al. [48] and might be due to increased 
erythropoietin production induced under hypoxic 
conditions [49]. The reduction of Hb concentration during 
exacerbation may be due to the release of hemoglobin 
and its derivative heme into tissue compartments where 
there are infection and inflammation [10].
Conclusion
Cp, haptoglobin, and hemopexin can be 
used as a panel of non-invasive biomarkers that 
reflect involvement of iron oxidative stress in asthma 
pathogenesis.
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